A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
Status:
RECRUITING
Trial end date:
2026-07-24
Target enrollment:
Participant gender:
Summary
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.